FLULAVAL QUADRIVALENT

STN: BL 125163
Proper Name: Influenza Vaccine
Tradename: FluLaval Quadrivalent
Manufacturer: ID Biomedical Corporation of Quebec
Indication:

• FLULAVAL is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.

Product Information

• Package Insert - FLULAVAL QUADRIVALENT

Supporting Documents

• July 1, 2026 Approval Letter - FLULAVAL
• July 13, 2023 Approval Letter - FLULAVAL QUADRIVALENT
• July 1, 2022 Approval Letter - FluLaval Quadrivalent
• July 2, 2021 Approval Letter - FluLaval
• July 2, 2020 Approval Letter - FluLaval
• February 6, 2020 Approval Letter - FluLaval
• July 2, 2019 Approval Letter - FluLaval
• June 29, 2018 Approval Letter - FluLaval Quadrivalent
• July 7, 2017 Approval Letter - FluLaval Quadrivalent
  To include the 2017-2018 United States formulation and associated labeling revisions.
• Statistical Review and Evaluation - FluLaval and FluLaval Quadrivalent
• Statistical Review Assay - FluLaval and FluLaval Quadrivalent
• Clinical Review - FluLaval and FluLaval Quadrivalent
• Supporting Documents older than three years - FluLaval Quadrivalent